Clinical Value of Translocator Protein Gene in Evaluating the Efficacy of FLT3-ITD/DNMT3A R882 Double-Mutated Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.01.007
- Author:
Shan-Hao TANG
1
;
Ying LU
1
;
Pi-Sheng ZHANG
1
;
Dong CHEN
1
;
Xu-Hui LIU
1
;
Xiao-Hong DU
1
;
Jun-Jie CAO
1
;
Shuang-Yue LI
1
;
Ke-Ya SHA
1
;
Lie-Guang CHEN
1
;
Xian-Xu ZHUANG
1
;
Pei-Pei YE
1
;
Li LIN
1
;
Ren-Zhi PEI
2
Author Information
1. Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
2. Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.E-mail: Peirz@163.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
translocator protein gene
- MeSH:
Humans;
DNA (Cytosine-5-)-Methyltransferases/genetics*;
DNA Methyltransferase 3A;
Mutation;
Leukemia, Myeloid, Acute/drug therapy*;
Nucleophosmin;
Prognosis;
fms-Like Tyrosine Kinase 3/genetics*;
Receptors, GABA/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(1):45-49
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical significance of translocator proteins (TSPO) gene in the treatment of FLT3-ITD/DNMT3A R882 double-mutated acute myeloid leukemia (AML).
METHODS:Seventy-six patients with AML hospitalized in the Department of Hematology of the Affiliated People's Hospital of Ningbo University from June 2018 to June 2020 were selected, including 34 patients with FLT3-ITD mutation, 27 patients with DNMT3A R882 mutation, 15 patients with FLT3-ITD/DNMT3A R882 double mutation, as well as 19 patients with immune thrombocytopenia (ITP) hospitalized during the same period as control group. RNA was routinely extracted from 3 ml bone marrow retained during bone puncture, and TSPO gene expression was detected by transcriptome sequencing (using 2-deltadeltaCt calculation).
RESULTS:The expression of TSPO gene in FLT3-ITD group and DNMT3A R882 group at first diagnosis was 2.02±1.04 and 1.85±0.76, respectively, which were both higher than 1.00±0.06 in control group, but the differences were not statistically significant (P=0.671, P=0.821). The expression of TSPO gene in the FLT3-ITD/DNMT3A R882 group was 3.98±1.07, wich was significantly higher than that in the FLT3-ITD group and DNMT3A R882 group, the differences were statistically significant (P=0.032, P=0.021). The expression of TSPO gene in patients who achieved complete response after chemotherapy in the FLT3-ITD/DNMT3A R882 group was 1.19±0.87, which was significantly lower than that at first diagnosis, and the difference was statistically significant (P=0.011).
CONCLUSION:TSPO gene may be used as an indicator of efficacy in FLT3-ITD /DNMT3A R882 double-mutated AML.
